公开(公告)号：US20170101408A1

公开(公告)日：2017-04-13

申请号：US15388327

申请日：2016-12-22

申请人： LUPIN LIMITED

发明人： Bhavesh DAVE ,  Rakesh Kumar BANERJEE ,  Samiron PHUKAN ,  Abhijit Datta KHOJE ,  Rajkumar HANGARGE ,  Jitendra Sambhaji JADHAV ,  Venkata P. PALLE ,  Rajender Kumar KAMBOJ

IPC分类号： C07D471/04 ,  A61K31/541 ,  A61K31/5377 ,  A61K45/06 ,  A61K31/519

CPC分类号： C07D471/04 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/541 ,  A61K45/06 ,  A61N5/10

摘要： The present disclosure is related to heteroaryl compounds as MEK inhibitors. These compounds include heteroaryl compounds of formula I, their pharmaceutically acceptable salts, combinations with suitable medicament and pharmaceutical compositions thereof. The present disclosure also includes processes of preparation of the compounds and their use in methods of treatment. The compounds as disclosed herein are of Formula (I) below:

公开(公告)号：US20160331753A1

公开(公告)日：2016-11-17

申请号：US15218980

申请日：2016-07-25

申请人： LUPIN LIMITED

发明人： Bhavesh DAVE ,  Rakesh Kumar BANERJEE ,  Samiron PHUKAN ,  Abhijit Datta KHOJE ,  Rajkumar HANGARGE ,  Jitendra Sambhaji JADHAV ,  Venkata P. PALLE ,  Rajender Kumar KAMBOJ

IPC分类号： A61K31/519 ,  A61N5/10 ,  A61K31/541 ,  A61K45/06 ,  A61K31/5377

CPC分类号： C07D471/04 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/541 ,  A61K45/06 ,  A61N5/10

摘要： The present disclosure is related to heteroaryl compounds as MEK inhibitors. These compounds include heteroaryl compounds of formula I, their pharmaceutically acceptable salts, combinations with suitable medicament and pharmaceutical compositions thereof. The present disclosure also includes processes of preparation of the compounds and their use in methods of treatment. The compounds as disclosed herein are of Formula (I) below:

公开(公告)号：US20170304299A1

公开(公告)日：2017-10-26

申请号：US15642899

申请日：2017-07-06

申请人： LUPIN LIMITED

发明人： Nageswara Rao IRLAPATI ,  Gokul Keruji DESHMUKH ,  Vijay Pandurang KARCHE ,  Santosh Madhukar JACHAK ,  Neelima SINHA ,  Venkata P. PALLE ,  Rajender Kumar KAMBOJ

IPC分类号： A61K31/497 ,  C07D413/14 ,  C07D413/10 ,  C07D261/12 ,  A61K31/496 ,  A61K31/4439 ,  A61K31/433 ,  A61K31/4245 ,  A61K31/423 ,  A61K31/422 ,  A61K31/421 ,  C07D417/14 ,  A61K31/42

CPC分类号： A61K31/497 ,  A61K31/42 ,  A61K31/421 ,  A61K31/422 ,  A61K31/423 ,  A61K31/4245 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/496 ,  C07D261/12 ,  C07D413/10 ,  C07D413/14 ,  C07D417/14

摘要： The present invention relates to compounds of Formula (I) along with processes for their preparation that are useful for treating, preventing and/or managing the diseases, disorders, syndromes or conditions associated with the modulation of CRAC. The invention further relates to methods of treating, preventing managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of CRAC of Formula (I).

公开(公告)号：US20170112840A1

公开(公告)日：2017-04-27

申请号：US15400627

申请日：2017-01-06

申请人： LUPIN LIMITED

发明人： Bhavesh DAVE ,  Rakesh Kumar BANERJEE ,  Samiron PHUKAN ,  Abhijit Datta KHOJE ,  Rajkumar HANGARGE ,  Jitendra Sambhaji JADHAV ,  Venkata P. PALLE ,  Rajender Kumar KAMBOJ

IPC分类号： A61K31/519 ,  A61K45/06

CPC分类号： C07D471/04 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/541 ,  A61K45/06 ,  A61N5/10

摘要： The present invention is related to heteroaryl compounds as MEK inhibitors. The invention includes heteroaryl compounds of formula I, their tautomers and pharmaceutically acceptable salts, combinations with suitable medicament and pharmaceutical compositions thereof. The present invention also includes process of preparation of the said compounds and intended use in therapy of them.

公开(公告)号：US20160304506A1

公开(公告)日：2016-10-20

申请号：US15186882

申请日：2016-06-20

申请人： LUPIN LIMITED

发明人： Nageswara Rao IRLAPATI ,  Zubair Abdul Wajid SHAIKH ,  Vijay Pandurang KARCHE ,  Gokul Keruji DESHMUKH ,  Neelima SINHA ,  Venkata P. PALLE ,  Rajender Kumar KAMBOJ

IPC分类号： C07D413/14 ,  C07D417/14 ,  C07D413/04

CPC分类号： C07D413/14 ,  C07D413/04 ,  C07D417/14

摘要： The present invention relates to compounds described herein Formula (I) and pharmaceutical acceptable salts thereof, which modulate the activity of calcium release-activated calcium (CRAC) channel. The invention also describes the compounds of Formula (I) and pharmaceutical compositions containing such compounds thereof for treating, managing, and/or lessening the severity of diseases, disorders, syndromes or conditions associated with the modulation of calcium release-activated calcium (CRAC) channel.

公开(公告)号：US20160145268A1

公开(公告)日：2016-05-26

申请号：US14899719

申请日：2014-06-20

申请人： LUPIN LIMITED

发明人： Nageswara Rao IRLAPATI ,  Nilesh Raghunath KHEDKAR ,  Ravindra Babanrao JAPE ,  Rahul Shripad NANDURDIKAR ,  Zubair Abdul Wajid SHAIKH ,  Neelima SINHA ,  Venkata P. PALLE ,  Rajender Kumar KAMBOJ

IPC分类号： C07D498/04 ,  C07D413/04 ,  C07D265/36 ,  C07D413/14 ,  C07D413/12 ,  C07D263/58 ,  C07D417/04

CPC分类号： C07D498/04 ,  A61K31/5377 ,  C07D263/58 ,  C07D265/36 ,  C07D413/04 ,  C07D413/12 ,  C07D413/14 ,  C07D417/04

摘要： The invention relates to compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine for the treatment of diseases, disorders associated with the modulation of calcium release-activated calcium (CRAC) channel. The invention also relates to pharmaceutical compositions containing such compounds in treating diseases disorders associated with calcium release-activated calcium (CRAC) channel modulators. wherein, ring D is Formula (a) or Formula (b): A and B, which may be same or different, are independently CR3 or N; Y is CR3 or N; L is selected from —NR2C(O)—, —C(O)NR2— and —NR2CRaRb—; Ra and Rb are independently hydrogen, halogen or substituted or unsubstituted alkyl; ring E is selected from the Formula (i) to (vii).

摘要翻译： 本发明涉及式（I）化合物及其药学上可接受的盐，其中取代基如本文所述，及其在药物中的用途，用于治疗与调节钙释放激活的钙（CRAC）通道相关的疾病，病症 。 本发明还涉及含有这些化合物在治疗与钙释放激活的钙（CRAC）通道调节剂相关的疾病障碍中的药物组合物。 其中环D为式（a）或式（b）：A和B可以相同或不同，独立地为CR 3或N; Y是CR3或N; L选自-NR 2 C（O） - ， - C（O）NR 2 - 和-NR 2 CR a R b - ; R a和R b独立地是氢，卤素或取代或未取代的烷基; 环E选自式（i）至（vii）。

公开(公告)号：US20220144852A1

公开(公告)日：2022-05-12

申请号：US17598524

申请日：2020-03-21

申请人： LUPIN LIMITED

发明人： Navnath Popat KARCHE ,  Moloy BANERJEE ,  Pradeep Rangrao PATIL ,  Vinod Popatrao VYAVAHARE ,  Deepak Sahebrao WALKE ,  Vaibhav Madhukar KALHAPURE ,  Vidya RAMDAS ,  Venkata P. PALLE ,  Rajender Kumar KAMBOJ

IPC分类号： C07D498/16

摘要： Disclosed are the macrocyclic compounds having the general Formula (I) and their tautomeric forms, stereoisomers, pharmaceutically acceptable salts, and their combination with suitable medicament, corresponding processes for the synthesis and pharmaceutical compositions and uses of compounds disclosed herein.

公开(公告)号：US20160137659A1

公开(公告)日：2016-05-19

申请号：US14900425

申请日：2014-06-23

申请人： LUPIN LIMITED

发明人： Nageswara Rao IRLAPATI ,  Kiran Chandrashekhar KULKARNI ,  Vijay Pandurang KARCHE ,  Gokul Keruji DESHMUKH ,  Neelima SINHA ,  Venkata P. PALLE ,  Rajender Kumar KAMBOJ

IPC分类号： C07D491/107 ,  C07D311/04 ,  C07D405/12 ,  C07D311/22 ,  C07D405/04

CPC分类号： C07D491/107 ,  C07D311/04 ,  C07D311/22 ,  C07D311/58 ,  C07D311/96 ,  C07D405/04 ,  C07D405/12 ,  C07D491/10 ,  C07D493/10

摘要： The invention relates to compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine for the treatment of diseases, disorders associated with the modulation of calcium release-activated calcium (CRAC) channel. The invention also relates to pharmaceutical compositions containing such compounds in treating diseases disorders associated with calcium release-activated calcium (CRAC) channel modulators.

摘要翻译： 本发明涉及式（I）化合物及其药学上可接受的盐，其中取代基如本文所述，及其在药物中的用途，用于治疗与调节钙释放激活的钙（CRAC）通道相关的疾病，病症 。 本发明还涉及含有这些化合物在治疗与钙释放激活的钙（CRAC）通道调节剂相关的疾病障碍中的药物组合物。

公开(公告)号：US20160022673A1

公开(公告)日：2016-01-28

申请号：US14840118

申请日：2015-08-31

申请人： LUPIN LIMITED

发明人： Nageswara Rao IRLAPATI ,  Gokul Keruji DESHMUKH ,  Vijay Pandurang KARCHE ,  Santosh Madhukar JACHAK ,  Neelima SINHA ,  Venkata P. PALLE ,  Rajender Kumar KAMBOJ

IPC分类号： A61K31/497 ,  A61K31/4439 ,  A61K31/433 ,  A61K31/422 ,  A61K31/423 ,  A61K31/421 ,  A61K31/496 ,  A61K31/42 ,  A61K31/4245

CPC分类号： A61K31/497 ,  A61K31/42 ,  A61K31/421 ,  A61K31/422 ,  A61K31/423 ,  A61K31/4245 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/496 ,  C07D261/12 ,  C07D413/10 ,  C07D413/14 ,  C07D417/14

摘要： The present invention relates to compounds of Formula (I) along with processes for their preparation that are useful for treating, preventing and/or managing the diseases, disorders, syndromes or conditions associated with the modulation of CRAC. The invention further relates to methods of treating, preventing managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of CRAC of Formula (I).

摘要翻译： 本发明涉及式（I）化合物及其制备方法，其可用于治疗，预防和/或控制与调节CRAC相关的疾病，病症，综合征或病症。 本发明还涉及治疗，预防管理和/或减轻与调节式（I）的CRAC相关的疾病，病症，综合征或病症的方法。

公开(公告)号：US20230066014A1

公开(公告)日：2023-03-02

申请号：US17782214

申请日：2020-12-02

申请人： Lupin Limited

发明人： Prathap Sreedharan NAIR ,  Ganesh Bhausaheb GUDADE ,  Shankar Bhaskar BHAGWAT ,  Amol Maruti YADAV ,  Chaitanya Prabhakar KULKARNI ,  Milind Dattatraya SINDKHEDKAR ,  Venkata P. PALLE ,  Rajender Kumar KAMBOJ

IPC分类号： A61K31/473 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/536 ,  A61P35/00

摘要： The invention relates to substituted nucleoside analogues of formula (I), pharmaceutically acceptable salts thereof and pharmaceutical compositions for treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme. The invention also relates to methods of treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme.